• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

神经内分泌前列腺癌的特异性特征鉴定：免疫状态、核心基因与治疗

Identification of the specific characteristics of neuroendocrine prostate cancer: Immune status, hub genes and treatment.

作者信息

Wang Jianqing, Wang Yu, Zhou Huihui, Yu Guopeng, Xu Huan, Gao Dajun, Li Minglun, Wang Yuzhuo, Xu Bin

机构信息

Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, China.

Vancouver Prostate Centre, Vancouver, BC, Canada; Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

出版信息

Transl Oncol. 2025 Apr;54:102320. doi: 10.1016/j.tranon.2025.102320. Epub 2025 Feb 24.

DOI:10.1016/j.tranon.2025.102320
PMID:39999729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11908612/
Abstract

Castration-resistant prostate cancer (CRPC) marks the advanced phase of prostate malignancy, manifested through two principal subtypes: castration-resistant adenocarcinoma (CRPC-adeno) and neuroendocrine prostate cancer (NEPC). This study aims to identify unique central regulatory genes, assess the immunological landscape, and explore potential therapeutic strategies specifically tailored to NEPC. We discovered 1444 differentially expressed genes (DEGs) distinguishing between the two cancer types and identified 12 critical hub genes. Notably, CHST1, MPPED2, and RIPPLY3 emerged as closely associated with the immune cell infiltration pattern, establishing them as top candidates. Prognostic analysis highlighted the potential critical roles of CHST1 and MPPED2 in prostate cancer development, findings corroborated through in vitro and in vivo assays. Moreover, we validated the functions and expression levels of CHST1, MPPED2, and RIPPLY3 in NEPC using cell lines, animal models and human tissues. In the final step, we found that imatinib might be the drug specific to NEPC, which was further confirmed by in vitro cell assay. Our results revealed the clinical characteristics, molecular features, immune cell infiltration pattern in CRPC-adeno and NEPC, and identified and confirmed CHST1, MPPED2, and RIPPLY3 as the critical genes in the development in prostate cancer and NEPC. We also predicted and validated imatinib as the potential specific drugs to NEPC.

摘要

去势抵抗性前列腺癌（CRPC）标志着前列腺恶性肿瘤的晚期阶段，主要表现为两种主要亚型：去势抵抗性腺癌（CRPC-腺）和神经内分泌前列腺癌（NEPC）。本研究旨在识别独特的核心调控基因，评估免疫格局，并探索专门针对NEPC的潜在治疗策略。我们发现了1444个区分这两种癌症类型的差异表达基因（DEG），并确定了12个关键的枢纽基因。值得注意的是，CHST1、MPPED2和RIPPLY3与免疫细胞浸润模式密切相关，使其成为首要候选基因。预后分析突出了CHST1和MPPED2在前列腺癌发展中的潜在关键作用，体外和体内试验证实了这些发现。此外，我们使用细胞系、动物模型和人体组织验证了CHST1、MPPED2和RIPPLY3在NEPC中的功能和表达水平。在最后一步中，我们发现伊马替尼可能是NEPC的特异性药物，体外细胞试验进一步证实了这一点。我们的结果揭示了CRPC-腺和NEPC的临床特征、分子特征、免疫细胞浸润模式，并确定并证实CHST1、MPPED2和RIPPLY3是前列腺癌和NEPC发展中的关键基因。我们还预测并验证了伊马替尼是NEPC的潜在特异性药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/ef4ece8a5c9f/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/a191483d3866/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/98e19e8ada61/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/ed1325cbe9ce/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/a8c7aacc5c72/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/19438c0960d2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/140696590697/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/dc3a03a1de3b/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/6a0ce9a63ba9/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/ef4ece8a5c9f/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/a191483d3866/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/98e19e8ada61/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/ed1325cbe9ce/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/a8c7aacc5c72/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/19438c0960d2/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/140696590697/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/dc3a03a1de3b/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/6a0ce9a63ba9/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f124/11908612/ef4ece8a5c9f/gr8.jpg

相似文献

1
Identification of the specific characteristics of neuroendocrine prostate cancer: Immune status, hub genes and treatment.神经内分泌前列腺癌的特异性特征鉴定：免疫状态、核心基因与治疗
Transl Oncol. 2025 Apr;54:102320. doi: 10.1016/j.tranon.2025.102320. Epub 2025 Feb 24.
2
Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.鉴定治疗相关性神经内分泌前列腺癌的新型诊断生物标志物。
Pathol Oncol Res. 2021 Sep 27;27:1609968. doi: 10.3389/pore.2021.1609968. eCollection 2021.
3
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.SRRM4 驱动前列腺腺癌在雄激素受体通路抑制下的神经内分泌转化。
Eur Urol. 2017 Jan;71(1):68-78. doi: 10.1016/j.eururo.2016.04.028. Epub 2016 May 11.
4
Treatment-induced neuroendocrine prostate cancer and neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors.治疗诱导的神经内分泌前列腺癌和神经内分泌前列腺癌：识别、预后与生存、遗传和表观遗传因素
World J Clin Cases. 2024 May 6;12(13):2143-2146. doi: 10.12998/wjcc.v12.i13.2143.
5
Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.左乙拉西坦的再利用以抑制神经内分泌前列腺癌并抑制肥大细胞支持腺癌。
Front Immunol. 2021 Mar 2;12:622001. doi: 10.3389/fimmu.2021.622001. eCollection 2021.
6
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.CEACAM5 的调控与抗 CEACAM5-SN38 抗体药物偶联物在神经内分泌前列腺癌中的治疗效果。
Clin Cancer Res. 2021 Feb 1;27(3):759-774. doi: 10.1158/1078-0432.CCR-20-3396. Epub 2020 Nov 16.
7
Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.雄激素剥夺治疗抵抗性前列腺癌和去势抵抗性神经内分泌前列腺癌模型中 NKX3.1 和 AURKA 轴的相互调控异常。
J Biomed Sci. 2021 Oct 8;28(1):68. doi: 10.1186/s12929-021-00765-z.
8
Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.治疗后出现的神经内分泌前列腺癌：94例临床病理及免疫组化分析
Front Oncol. 2021 Feb 1;10:571308. doi: 10.3389/fonc.2020.571308. eCollection 2020.
9
Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.GIT1 基因的选择性剪接与神经内分泌前列腺癌有关。
Cancer Sci. 2019 Jan;110(1):245-255. doi: 10.1111/cas.13869. Epub 2018 Dec 12.
10
Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients.用于检测去势抵抗性前列腺癌患者治疗诱导的神经内分泌分化的新型非侵入性标志物。
Sci Rep. 2021 Apr 15;11(1):8279. doi: 10.1038/s41598-021-87441-2.

本文引用的文献

1
The extracellular matrix integrates mitochondrial homeostasis.细胞外基质整合了线粒体的稳态。
Cell. 2024 Aug 8;187(16):4289-4304.e26. doi: 10.1016/j.cell.2024.05.057. Epub 2024 Jun 27.
2
Extracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells.细胞外基质线索调节癌细胞的机械感知和机械转导。
Cells. 2024 Jan 2;13(1):96. doi: 10.3390/cells13010096.
3
AZGP1P2/UBA1/RBM15 Cascade Mediates the Fate Determinations of Prostate Cancer Stem Cells and Promotes Therapeutic Effect of Docetaxel in Castration-Resistant Prostate Cancer via TPM1 m6A Modification.
AZGP1P2/UBA1/RBM15级联反应通过TPM1 m6A修饰介导前列腺癌干细胞的命运决定并增强多西他赛在去势抵抗性前列腺癌中的治疗效果。
Research (Wash D C). 2023 Oct 17;6:0252. doi: 10.34133/research.0252. eCollection 2023.
4
Mechanotransduction in response to ECM stiffening impairs cGAS immune signaling in tumor cells.细胞外基质硬度增加引发的机械转导会损害肿瘤细胞中的 cGAS 免疫信号转导。
Cell Rep. 2023 Oct 31;42(10):113213. doi: 10.1016/j.celrep.2023.113213. Epub 2023 Oct 5.
5
Remodeling Tumor Immune Microenvironment by Using Polymer-Lipid-Manganese Dioxide Nanoparticles with Radiation Therapy to Boost Immune Response of Castration-Resistant Prostate Cancer.利用聚合物-脂质-二氧化锰纳米颗粒联合放射治疗重塑肿瘤免疫微环境以增强去势抵抗性前列腺癌的免疫反应
Research (Wash D C). 2023 Oct 3;6:0247. doi: 10.34133/research.0247. eCollection 2023.
6
Synthetic Gene Circuit-Based Assay with Multilevel Switch Enables Background-Free and Absolute Quantification of Circulating Tumor DNA.基于合成基因电路的多级开关检测实现循环肿瘤DNA的无背景绝对定量。
Research (Wash D C). 2023 Oct 2;6:0217. doi: 10.34133/research.0217. eCollection 2023.
7
The 'New (Nu)-clear' evidence for the tumor-driving role of PI3K.PI3K肿瘤驱动作用的“新（核）”证据。
Acta Mater Med. 2022;1(2):193-196. doi: 10.15212/amm-2022-0013. Epub 2022 May 16.
8
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.肿瘤进展和免疫逃逸中的细胞外基质重塑：从机制到治疗。
Mol Cancer. 2023 Mar 11;22(1):48. doi: 10.1186/s12943-023-01744-8.
9
Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer.前列腺腺癌和神经内分泌前列腺癌的临床病理和免疫特征。
World J Surg Oncol. 2022 Dec 27;20(1):407. doi: 10.1186/s12957-022-02841-6.
10
KIT as a therapeutic target in neuroendocrine prostate cancer.作为神经内分泌前列腺癌治疗靶点的 KIT。
Cancer Cell. 2022 Nov 14;40(11):1266-1268. doi: 10.1016/j.ccell.2022.10.010. Epub 2022 Nov 3.